Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Fuchs, R; Schraml, E; Leitinger, G; Letofsky-Papst, I; Stelzer, I; Haas, HS; Schauenstein, K; Sadjak, A.
á1-adrenergic drugs exhibit affinity to a thapsigargin-sensitive binding site and interfere with the intracellular Ca2+ homeostasis in human erythroleukemia cells.
Exp Cell Res. 2011; 317(20):2969-2980
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Fuchs Robert
Haas Helga Susanne
Leitinger Gerd
Sadjak Anton
Schauenstein Konrad
Schraml Elisabeth
Stelzer Ingeborg
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Even though the erythroleukemia cell lines K562 and HEL do not express á1-adrenoceptors, some á1-adrenergic drugs influence both survival and differentiation of these cell lines. Since Ca2+ is closely related to cellular homeostasis, we examined the capacity of á1-adrenergic drugs to modulate the intracellular Ca2+ content in K562 cells. Because of morphological alterations of mitochondria following á1-adrenergic agonist treatment, we also scrutinized mitochondrial functions. In order to visualize the non-adrenoceptor binding site(s) of á1-adrenergic drugs in erythroleukemia cells, we evaluated the application of the fluorescent á1-adrenergic antagonist BODIPY® FL-Prazosin. We discovered that the á1-adrenergic agonists naphazoline, oxymetazoline and also the á1-adrenergic antagonist benoxathian are able to raise the intracellular Ca2+-content in K562 cells. Furthermore, we demonstrate that naphazoline treatment induces ROS-formation as well as an increase in Äψm in K562 cells. Using BODIPY® FL-Prazosin we were able to visualize the non-adrenoceptor binding site(s) of á1-adrenergic drugs in erythroleukemia cells. Interestingly, the SERCA-inhibitor thapsigargin appears to interfere with the binding of BODIPY® FL-Prazosin. Our data suggest that the effects of á1-adrenergic drugs on erythroleukemia cells are mediated by a thapsigargin sensitive binding site, which controls the fate of erythroleukemia cells towards differentiation, senescence and cell death through modulation of intracellular Ca2+. Copyright © 2011 Elsevier Inc. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Adrenergic Agents - pharmacology
Adrenergic alpha-1 Receptor Agonists - pharmacology
Adrenergic alpha-1 Receptor Antagonists - pharmacology
Aging - drug effects
Binding Sites - drug effects
Calcium - metabolism
Cell Death - drug effects
Cell Differentiation - drug effects
Cell Line, Tumor -
Cell Survival - drug effects
Homeostasis - drug effects
Humans -
K562 Cells -
Leukemia, Erythroblastic, Acute - drug therapy
Membrane Potential, Mitochondrial - drug effects
Mitochondria - drug effects
Mitochondrial Membranes - drug effects
Naphazoline - pharmacology
Reactive Oxygen Species - metabolism
Receptors, Adrenergic, alpha-1 - metabolism
Sarcoplasmic Reticulum Calcium-Transporting ATPases - antagonists and inhibitors
Thapsigargin - pharmacology

Find related publications in this database (Keywords)
Erythroleukemia cells
alpha 1-adrenergic drugs
Mitochondria
Calcium
Reactive oxygen species
© Meduni Graz Impressum